Does Structured Reporting Improve Lung Cancer Reports?
-
By
-
Andrea Surnit
-
July 2, 2026
-
3 min
By
Andrea Surnit
July 2, 2026
In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.
September 21, 2026
Combining IL-17 with TNF-alpha showed strong discrimination between carious lesions and healthy controls, but performance was more modest against gingival inflammation.
September 9, 2026
Investigators compared intra-articular microbial profiles and predicted metabolic pathways in patients with hip osteoarthritis and nonarthritic controls.
September 4, 2026